RAVAGLIA, SABRINA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.402
EU - Europa 1.158
AS - Asia 638
SA - Sud America 3
OC - Oceania 2
AF - Africa 1
Totale 3.204
Nazione #
US - Stati Uniti d'America 1.399
CN - Cina 589
IE - Irlanda 371
IT - Italia 204
UA - Ucraina 169
FI - Finlandia 149
DE - Germania 130
GB - Regno Unito 51
SG - Singapore 31
SE - Svezia 28
FR - Francia 19
BE - Belgio 13
JP - Giappone 9
IN - India 8
CZ - Repubblica Ceca 5
NL - Olanda 4
CA - Canada 3
CH - Svizzera 3
BR - Brasile 2
ES - Italia 2
GR - Grecia 2
LU - Lussemburgo 2
RU - Federazione Russa 2
AT - Austria 1
AU - Australia 1
CL - Cile 1
DK - Danimarca 1
KR - Corea 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 3.204
Città #
Chandler 376
Dublin 368
Jacksonville 206
Nanjing 163
Boardman 116
Ashburn 97
Beijing 72
Nanchang 60
Helsinki 57
Milan 55
Ann Arbor 52
Jiaxing 52
Lawrence 50
Princeton 50
Medford 49
Hebei 48
Changsha 46
Shenyang 41
Wilmington 41
Pavia 37
Hangzhou 30
New York 30
Shanghai 29
Singapore 20
Tianjin 20
Trieste 14
Verona 14
Brussels 13
Bergamo 12
Munich 11
Woodbridge 10
Tokyo 9
Los Angeles 7
Seattle 7
Turin 7
Kunming 6
Lodi 6
Norwalk 6
Pune 6
Brno 5
Fairfield 5
Modena 5
Piscataway 5
Travaco Siccomario 5
Como 4
Dresden 4
Hanover 4
Rome 4
Washington 4
Auburn Hills 3
Cork 3
Dallas 3
Naples 3
Saluzzo 3
San Francisco 3
Toronto 3
Amsterdam 2
Athens 2
Bologna 2
Brembate di Sopra 2
Catania 2
Changchun 2
Des Moines 2
Esch-sur-Alzette 2
Falkenstein 2
Udine 2
Vercelli 2
Zhengzhou 2
Zurich 2
Alexandria 1
Altoona 1
Auckland 1
Buccinasco 1
Casalpusterlengo 1
Edinburgh 1
Fes 1
Florence 1
Fremont 1
Fuzhou 1
Guangzhou 1
Houston 1
Jinan 1
Krasnoyarsk 1
Lanzhou 1
Leidschendam 1
London 1
Macerata 1
Madrid 1
Marmirolo 1
Messina 1
Monfalcone 1
Ningbo 1
Orange 1
Redwood City 1
San Genesio ed Uniti 1
Shijiazhuang 1
Skopje 1
Sydney 1
Taizhou 1
Torino 1
Totale 2.416
Nome #
Mapping the human genetic architecture of COVID-19 133
A first update on mapping the human genetic architecture of COVID-19 85
Enzyme replacement therapy (ERT) in adult-onset type II glycogenosis (GSDII) 83
A Chaperone Enhances Blood α-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy. 83
Cognitive impairment and central motor conduction time in chronic alcoholics. 81
Severe recurrent myelitis in patients with hepatitis C virus infection 71
Dietary treatment in adult-onset type II glycogenosis. 70
The angiotensin-converting enzyme insertion/deletion polymorphysm modifies the clinical outcome in patients with Pompe disease. 70
Clinical MRI dissociation in myelopathy: a clue to sarcoidosis? 69
Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. 67
Pathogenetic role of myelitis for syringomyelia. 65
Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encphalomyelitis. 65
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant. 65
Efficacy of propafenone in paramyotonia congenita 64
Recombinant alpha-glucosidase in adult-onset type II glycogenosis: The experience with the first Italian patient, from expanded access programmes to marketing authorization 64
Aspetti clinici e patogenetici della comorbidita’ emicranica. 64
Changes in nutritional status and body composition during enzyme replacementtherapy in adult-onset type II glycogenosis. 64
Emicrania emiplegica familiare: dalla genetica alla clinica. 63
Triggering migraine attacks:the role of nitroderivatives. 63
Combined central and peripheral demyelination: comparison of adult and pediatric series 62
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 62
Immune-mediated neuropathies in myeloma patients treated with bortezomib. 62
Presyrinx in children with Chiari malformations 61
Severe recurrent myelitis in patients with hepatitis C virus infection patients 59
Retinal migraine as unusual feature of cerebral autosomal dominantarteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL) 59
Early-onset ptosis in type II glycogenosis 59
Outcome after Two Years of Enzyme Replacement Therapy (ERT) in 29 Patients with Late-Onset Type II Glycogenosis (GSDII) 58
Recombinant alglucosidase alpha (rhGAA) in adult-onset type II glycogenosis (GSDII): A follow-up study before and after treatment 54
NMO-IgG-negative relapsing myelitis 53
Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease. 53
Strabismo parossistico: Meccanismi corticali e meccanismi periferici nella fisiopatologia di due casi con analoga fenomenologia critica 52
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patientswith Alzheimer's disease and vascular dementia. 52
LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population 50
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 49
Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset Type II Glycogenosis? 48
Enzyme replacement therapy in severe adult-onset glycogen storage disease type II 48
Post-infectious inflammatory disordes:sub-groups based on prospective follow-up. 47
Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. 46
Enzyme replacement therapy in late-onset type II glycogenosis. 45
Erectile dysfunction as a sentinel symptom ofcardiovascular autonomic neuropathy in heavy drinkers 44
RECOMBINANT ALGLUCOSIDASE ALFA IN ADULT-ONSET GLYCOGENOSIS TYPE II: A FOLLOW-UP STUDY BEFORE AND AFTER TREATMENT 44
The diagnosis of migraine: clinical and instrumental aspects 43
Genotype-phenotype correlation in Pompe disease, a step forward. 42
Ocular neuromyotonia with both tonic and paroxysmal components due to vascular compression 41
Enzyme replacement therapy in adult-onset type II glycogenosis 41
Severe steroid-resistant post-infectious encephalomyelitis: General features and effects of IVIg 41
Post-infectious and postvaccinal acute disseminated encephalomyelitis occurring in the same patients 39
Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up 38
Guillain-Barré syndrome associated with SARS-CoV-2 38
Diagnosis and therapy of acute disseminated encephalomyelitis and its variants 38
Erratum: Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (Journal of Neurology (2014) 261 (438-440) DOI: 10.1007/s00415-013-7217-3) 38
null 34
COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course 33
Adult-onset type II glycogenosis (GSDII): Clinical spectrum and enzyme replacement therapy (ERT) 32
ENZYME REPLACEMENT THERAPY IN LATE-ONSET PHENOTYPES OF GLYCOGENOSIS TYPE 2: RESULTS OF AN ITALIAN MULTICENTER STUDY 32
Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2 30
Trunk muscle involvement in late-onset Pompe disease: Study of thirty patients 28
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 26
Enzyme replacement therapy with Alglucosidase alfa in juvenile-adult glycogenosis type 2 patients 26
HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review 26
Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? 23
Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD) 21
Totale 3.266
Categoria #
all - tutte 12.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.366


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020500 0 276 1 33 2 35 4 35 3 49 61 1
2020/2021284 39 29 6 33 3 39 2 44 6 40 36 7
2021/2022221 5 3 4 3 0 4 3 11 11 2 36 139
2022/20231.202 84 90 12 174 97 123 2 61 438 13 96 12
2023/2024398 49 73 11 18 28 102 5 26 5 10 19 52
2024/2025106 34 72 0 0 0 0 0 0 0 0 0 0
Totale 3.266